会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 96. 发明申请
    • Dosage form and method for producing the same
    • 用途及其制备方法
    • US20050152977A1
    • 2005-07-14
    • US10512860
    • 2004-03-02
    • Hans-Ulrich PetereitChristian MeierKlaus Schultes
    • Hans-Ulrich PetereitChristian MeierKlaus Schultes
    • A61K9/28A61K9/32A61K9/24
    • A61K9/2846Y02A50/473
    • The invention relates to a process for producing a coated drug form or a drug form in the form of an active ingredient matrix, by processing a copolymer, an active pharmaceutical ingredient, a core if present and/or pharmaceutically customary excipients in a conventional manner by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading, spraying or compression to form a coated drug form and/or to form an active ingredient matrix, characterized in that a copolymer is used which is composed of 20 to 33% by weight methacrylic acid, 5 to 30% by weight methyl acrylate, 20 to 40% by weight ethyl acrylate and more than 10 to 30% by weight butyl methacrylate and, if desired, 0 to 10% by weight further vinylically copolymerizable monomers, with the proviso that the glass transition temperature of the copolymer in accordance with ISO 11357-2, section 3.3.3, is 55 to 70° C. The invention further relates to the drug form produced in accordance with the invention, to the copolymer, and to the use thereof.
    • 本发明涉及通过以常规方式加工共聚物,活性药物成分,核心(如果存在)和/或药学上常规的赋形剂来生产呈活性成分基质形式的包被药物形式或药物形式的方法 熔融,注射成型,挤出,湿法制粒,浇铸,浸涂,铺展,喷雾或压缩以形成涂覆的药物形式和/或形成活性成分基质,其特征在于使用共聚物,其由20-33% 的甲基丙烯酸,5至30重量%的丙烯酸甲酯,20至40重量%的丙烯酸乙酯和大于10至30重量%的甲基丙烯酸丁酯,以及如果需要,0至10重量%的进一步的乙烯基共聚单体, 条件是根据ISO 11357-2,第3.3.3节的共聚物的玻璃化转变温度为55至70℃。本发明还涉及根据本发明生产的药物形式至th e共聚物,以及其用途。